NCT04817956: IMPRESS-N

Improving Public Cancer Care by Implementing Precision Medicine in Norway

Recruiting now Phase 2 Last updated 29 February 2024

What this trial tests

Phase 2 trial testing Atezolizumab in Cancer Metastatic in 3,000 participants. Currently enrolling.

Timeline

1 April 2021

Primary endpoint
30 March 2040

30 April 2045

Quick facts

Lead sponsor	Oslo University Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	3,000
Start date	1 April 2021
Primary completion	30 March 2040
Estimated completion	30 April 2045
Sites	17 locations across Norway

Drugs / interventions tested

• Atezolizumab (atezolizumab) — full drug profile →

Conditions studied

• Cancer Metastatic — all drugs for Cancer Metastatic →

Sponsor

Oslo University Hospital

Who can join

16 and older, any sex, with Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

IMPRESS-Norway is a prospective, non-randomized clinical trial evaluating efficacy of commercially available, anti-cancer drugs prescribed for patients with advanced cancer diagnosed with potentially actionable alterations as revealed by molecular diagnostics. IMPRESS-Norway is a nation-wide study and all hospitals with an oncology and / or hematology department will be invited to participate in the study. The study will use a combined umbrella and basket design and a Simon two-stage model of expanding cohorts to follow up potentially effective combinations of biomarker and drug on specific indications. Sampling of biological material will be performed at presentation, during treatment and upon progression. Additional biomarker and translational analyses including whole genome sequencing (WGS) on tumour material and liquid biopsies, identifying mechanisms underlying drug sensitivity versus resistance will be performed.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
   Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, et al · · 2023 · cited 203× · PMID 37059834 · DOI 10.1038/s41591-023-02321-8
2. Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.
   Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, et al · · 2022 · cited 24× · PMID 35568909 · DOI 10.1186/s12967-022-03432-5
3. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
   Kringelbach T, Højgaard M, Rohrberg K, Spanggaard I, et al · · 2023 · cited 21× · PMID 36814246 · DOI 10.1186/s12885-023-10632-9
4. Standardized assays to monitor drug sensitivity in hematologic cancers.
   Ayuda-Durán P, Hermansen JU, Giliberto M, Yin Y, et al · · 2023 · cited 12× · PMID 38040674 · DOI 10.1038/s41420-023-01722-5
5. IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results.
   Puco K, Fagereng GL, Brabrand S, Niehusmann P, et al · · 2024 · cited 9× · PMID 38779911 · DOI 10.2340/1651-226x.2024.28322
6. Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities.
   Stamatopoulos K, Pavlova S, Al-Sawaf O, Chatzikonstantinou T, et al · · 2024 · cited 5× · PMID 39035106 · DOI 10.1002/hem3.113
7. Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient.
   Hermansen JU, Athanasiadis P, Yin Y, Rise AF, et al · · 2025 · cited 2× · PMID 40701968 · DOI 10.1038/s41419-025-07884-7
8. Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial.
   Slørdahl KS, Puco K, Falk RS, Dyvik I, et al · · 2026 · cited 1× · PMID 41664938 · DOI 10.2340/1651-226x.2026.45086